| Fry Eye Associates Pa | |
|
502 College Street, Garden City, KS 67846-6183 | |
| (620) 275-7248 | |
| (620) 275-5262 |
| Full Name | Fry Eye Associates Pa |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 502 College Street, Garden City, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124049499 | NPI | - | NPPES |
| 100722450A | Medicaid | OK | |
| 94001922 | Medicaid | CO | |
| 100215250A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Secondary |
| 207W00000X | Ophthalmology | (* (Not Available)) | Primary |
| Provider Name | Luther L. Fry |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1205858776 PECOS PAC ID: 6709797871 Enrollment ID: I20050502000392 |
News Archive
NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported that it has entered into a new agreement with GlaxoSmithKline (GSK), that terminates and replaces a prior collaborative research and license agreement between NPS and GSK from 1993, which focused on the discovery and development of small molecule antagonists of the calcium receptor that increase secretion of parathyroid hormone.
Midlothian Laboratories, a division of Hi-Tech Pharmacal Co., Inc., as part of its continuing humanitarian relief efforts, recently donated more than $3 million worth of essential vitamins and nutritional supplements to AmeriCares for people in the developing world living in extreme poverty and suffering from chronic malnutrition.
Veracyte, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Veracyte, Inc.
Five years of hard work and a little "cosmic luck" led Rice University researchers to a new method to obtain structural details on molecules in biomembranes.
› Verified 6 days ago
| Provider Name | William S Clifford |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1114941226 PECOS PAC ID: 3173563020 Enrollment ID: I20050510000602 |
News Archive
NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported that it has entered into a new agreement with GlaxoSmithKline (GSK), that terminates and replaces a prior collaborative research and license agreement between NPS and GSK from 1993, which focused on the discovery and development of small molecule antagonists of the calcium receptor that increase secretion of parathyroid hormone.
Midlothian Laboratories, a division of Hi-Tech Pharmacal Co., Inc., as part of its continuing humanitarian relief efforts, recently donated more than $3 million worth of essential vitamins and nutritional supplements to AmeriCares for people in the developing world living in extreme poverty and suffering from chronic malnutrition.
Veracyte, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Veracyte, Inc.
Five years of hard work and a little "cosmic luck" led Rice University researchers to a new method to obtain structural details on molecules in biomembranes.
› Verified 6 days ago
| Provider Name | Eric L Fry |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1538373485 PECOS PAC ID: 7214010586 Enrollment ID: I20080208000472 |
News Archive
NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported that it has entered into a new agreement with GlaxoSmithKline (GSK), that terminates and replaces a prior collaborative research and license agreement between NPS and GSK from 1993, which focused on the discovery and development of small molecule antagonists of the calcium receptor that increase secretion of parathyroid hormone.
Midlothian Laboratories, a division of Hi-Tech Pharmacal Co., Inc., as part of its continuing humanitarian relief efforts, recently donated more than $3 million worth of essential vitamins and nutritional supplements to AmeriCares for people in the developing world living in extreme poverty and suffering from chronic malnutrition.
Veracyte, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Veracyte, Inc.
Five years of hard work and a little "cosmic luck" led Rice University researchers to a new method to obtain structural details on molecules in biomembranes.
› Verified 6 days ago
| Provider Name | Reed Allan Mcatee |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1003346032 PECOS PAC ID: 1850665886 Enrollment ID: I20170914002425 |
News Archive
NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported that it has entered into a new agreement with GlaxoSmithKline (GSK), that terminates and replaces a prior collaborative research and license agreement between NPS and GSK from 1993, which focused on the discovery and development of small molecule antagonists of the calcium receptor that increase secretion of parathyroid hormone.
Midlothian Laboratories, a division of Hi-Tech Pharmacal Co., Inc., as part of its continuing humanitarian relief efforts, recently donated more than $3 million worth of essential vitamins and nutritional supplements to AmeriCares for people in the developing world living in extreme poverty and suffering from chronic malnutrition.
Veracyte, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Veracyte, Inc.
Five years of hard work and a little "cosmic luck" led Rice University researchers to a new method to obtain structural details on molecules in biomembranes.
› Verified 6 days ago
| Provider Name | Travis Kimple |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1114450566 PECOS PAC ID: 1052669322 Enrollment ID: I20210804002202 |
News Archive
NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported that it has entered into a new agreement with GlaxoSmithKline (GSK), that terminates and replaces a prior collaborative research and license agreement between NPS and GSK from 1993, which focused on the discovery and development of small molecule antagonists of the calcium receptor that increase secretion of parathyroid hormone.
Midlothian Laboratories, a division of Hi-Tech Pharmacal Co., Inc., as part of its continuing humanitarian relief efforts, recently donated more than $3 million worth of essential vitamins and nutritional supplements to AmeriCares for people in the developing world living in extreme poverty and suffering from chronic malnutrition.
Veracyte, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Veracyte, Inc.
Five years of hard work and a little "cosmic luck" led Rice University researchers to a new method to obtain structural details on molecules in biomembranes.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fry Eye Associates Pa 502 College Street, Garden City, KS 67846-6183 Ph: (620) 275-7248 | Fry Eye Associates Pa 502 College Street, Garden City, KS 67846-6183 Ph: (620) 275-7248 |
News Archive
NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported that it has entered into a new agreement with GlaxoSmithKline (GSK), that terminates and replaces a prior collaborative research and license agreement between NPS and GSK from 1993, which focused on the discovery and development of small molecule antagonists of the calcium receptor that increase secretion of parathyroid hormone.
Midlothian Laboratories, a division of Hi-Tech Pharmacal Co., Inc., as part of its continuing humanitarian relief efforts, recently donated more than $3 million worth of essential vitamins and nutritional supplements to AmeriCares for people in the developing world living in extreme poverty and suffering from chronic malnutrition.
Veracyte, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Veracyte, Inc.
Five years of hard work and a little "cosmic luck" led Rice University researchers to a new method to obtain structural details on molecules in biomembranes.
› Verified 6 days ago